Spin-out of Northwestern University, Sibel Health, has unveiled its physiological monitoring platform called Discovery for use in clinical trials.
Discovery employs FDA-cleared wearable sensors to track participants' vital signs and digital endpoints during clinical trials, such as heart rate, blood pressure, SpO2, respiratory rate, and temperature.
Sibel Health has also partnered with Medidata, an AI-powered clinical trial solutions company, to integrate Discovery into their cloud-based platform, enabling pharmaceutical companies and research organisations to access Sibel's data. This collaboration aims to accelerate clinical research and transform healthcare practices.
The company previously received FDA clearance for its ANNE One platform, designed for continuous neonate and vital sign monitoring of infants, and raised $33 million in Series B funding in August.
Click here to read the original news story.